Join the club for FREE to access the whole archive and other member benefits.

Cambridge Oncometrix

Company that develops test for early detection of prostate cancer

Prostate cancer is one of the most frequent cancers globally. 1 out of 8 men will develop prostate cancer once in their lifetime. High incidence of the disease makes a reliable early diagnostic vital for better treatment outcomes. Current prostate cancer detection pathway is still very inaccurate and leads in over half of the cases to unnecessary prostate biopsies, where no cancer is found.

Cambridge Oncometrix has developed a revolutionary non-invasive pre-biopsy diagnostic test that allows for much-improved prostate cancer risk assessment in primary and secondary care.

Visit website: https://cambridgeoncometrix.com/

 cambridgeoncometrix

 cambridge-oncometrix-limited

 COncometrix

Details last updated 20-Sep-2019

Topics mentioned on this page:
Cancer